key: cord-0962769-wqma6ilr authors: Lalabekyan, Dr Bagrat; Kunst, Professor Gudrun; Skelton, Dr Vanessa A title: Torsade de Pointes in COVID-19 infection date: 2020-07-15 journal: J Cardiothorac Vasc Anesth DOI: 10.1053/j.jvca.2020.07.038 sha: 4f25f768773035c4b43b768207b5c8fa26cd9965 doc_id: 962769 cord_uid: wqma6ilr nan This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. A 73 year old man (weight 69kg, height 175cm) was transferred to our critical care unit with respiratory and acute renal failure secondary to COVID-19 infection. His past medical history included hypertension, diabetes and previous stroke, from which he had made a full recovery. The patient was treated with mechanical ventilation and peritoneal dialysis. He was recruited into the hydroxychloroquine arm of the RECOVERY (Randomised Evaluation of COVID-19 Therapy) trial. Baseline electrocardiogram (ECG) and subsequent ECG monitoring were normal and did not demonstrate any QT prolongation. Three days later, the patient was witnessed to develop a ventricular tachycardia with a circulatory collapse. Immediate cardiopulmonary resuscitation was initiated and defibrillator pads attached, however the arrhythmia self-terminated within 2 minutes (Fig 1) . After resuscitation, another ECG showed a normal QT interval. Arterial blood gas analysis did not show any signs of respiratory insufficiency or an acid-base disturbance. There were no signs of myocardial ischemia. A full panel of blood tests was performed which did not demonstrate any relevant abnormalities in full blood count, biochemical studies or coagulation. Hypomagnesemia or hypokalemia were absent. Echocardiography was normal. What is the diagnosis? Diagnosis: Torsade de pointes ventricular tachycardia presumably resulting from hydroxychloroquine therapy. Review of the telemetry data demonstrated a polymorphic ventricular tachycardia in the pattern of torsades de pointes with a spontaneous onset and termination. A cardiac electrophysiology review was requested and confirmed the diagnosis of torsades de pointes. Review of ECGs, blood test results and medication history allowed us to conclude that the arrhythmia had most likely been caused by hydroxychloroquine. Recommendations were made for stringent monitoring of serum electrolytes (to prevent hypomagnesaemia and hypokalemia) and daily ECGs. No further antiarrhythmic therapy was recommended at this stage. Hydroxychloroquine was discontinued and the patient's participation in the RECOVERY trial was terminated. No further arrhythmias were reported during the patent's stay. An adverse drug reaction report was submitted to the UK Medicines and Healthcare products Regulatory Agency (UK MHRA) to register the hydroxychloroquine related lifethreatening arrhythmia. In early 2020 during the COVID-19 pandemic a number of studies reported possible therapeutic effects of hydroxychloroquine and it was therefore included as one of the drugs in the platform UK RECOVERY trial. 1 However, preliminary data showed no benefit in hospitalized patients with COVID-19 which led to the UK MHRA instruction to stop recruitment into trials using hydroxychloroquine to treat COVID-19. 2 Hydroxychloroquine was introduced in 1955 as an anti-malarial drug. It has immunomodulatory properties which include inhibition of chemotaxis and phagocytosis, reduction of cytokine synthesis, inhibition of phospholipase A2 and signaling in lymphocytes. 3, 4 Hydroxychloroquine has a large spectrum of side effects including cardiomyopathy and arrhythmias associated with the prolongation of the QT interval. 3 Between 1964 and 2020 the UK MHRA registered 916 cases of adverse drug reactions, of which 679 were classified as serious and 15 as fatal. The most commonly reported adverse drug reactions involved skin (454 cases), nervous system, including eye (285) and gastrointestinal tract (165). Cardiac adverse drug reactions were reported in 48 cases and included myocardial and/or pericardial disorders, arrhythmias, and heart failure. 5 Cardiac arrhythmias were reported in 18 cases. Anesthesiologists should continue to be aware of the importance of a comprehensive drug history, and are reminded of potential life-threatening arrhythmias when hydroxychloroquine is used. Duration of a single ECG strip is 15 seconds. RECOVERY intervention sheet -hydroxychloroquine (recruitment closed) 18/04/2020 UK Medicines & Healthcare products Regulatory Agency. MHRA suspends recruitment to COVID-19 hydroxychloroquine trials Hydroxychloroquine: From Malaria to Autoimmunity New concepts in antimalarial use and mode of action in dermatology UK Medicines & Healthcare products Regulatory Agency. Interactive drug analysis profile for Hydroxychloroquine The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.